Last reviewed · How we verify
NCT03601013
Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy and Mean Precise-DAPT and DAPT Scores in Turkey
trial testing Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy in Anti-platelet Therapy in 963 participants. Completed in 1 March 2019.
1 November 2018
Quick facts
| Lead sponsor | Cardiovascular Academy Society, Turkey |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 963 |
| Start date | 1 March 2018 |
| Primary completion | 1 November 2018 |
| Estimated completion | 1 March 2019 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy
Conditions studied
- Anti-platelet Therapy — all drugs for Anti-platelet Therapy →
Sponsor
Cardiovascular Academy Society, Turkey
Who can join
18 and older, any sex, with Anti-platelet Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Coronary Artery Disease (CAD) is leading cause of death worldwide. Most of them underwent coronary angiography and they have to use dual anti-platelet therapy. As mentioned novel guidelines for CAD, the estimated number of patients requiring dual anti-platelet therapy has increased over time, and DAPT time is controversial. Acting on the behalf of 2017 ESC focused update on dual anti-platelet therapy in coronary artery disease developed in collaboration with EACTS guideline, this study is amid to determine PRECISE-DAPT score which predicts out of hospital bleeding risk in patients receiving dual anti-platelet treatment and to detect the prevalence of patients with high bleeding risk, and to determine DAPT score which predicts benefit/risk ratio of continuing or discontinuing dual ant-iplatelet therapy after 12 months and to detect the prevalence of patients with high ischemic or hemorrhagic complication risk in centers included in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03601013
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Cardiovascular Academy Society, Turkey trials
Trials by the same sponsor.
- NCT04275882 — Demographical and Clinical Profile of Patients With Left Ventricular Hypertrophy · completed
- NCT03727984 — Re-hospitalized Patients With Acute Coronary Syndrome · completed
- NCT03364387 — Myocardial Infarction With Non-obstructive Coronary Arteries in Turkish Population · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03601013 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cardiovascular Academy Society, Turkey
- Last refreshed: 7 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03601013.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing